Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-DA-25-008

Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R21 Clinical Trial Not Allowed)

Closed on August 13, 2024.

Posted
December 20, 2023
Close date
August 13, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $652,625 in first-year total cost, median $326,313.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 MXY-N (J2)]2

Most frequent institutions

  1. DREXEL UNIVERSITY1
  2. GEORGETOWN UNIVERSITY1
Competing awards under RFA-DA-25-008 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Transcriptional silencing of HIV by LTR targeting RNAi1R21DA063133-01KLASE, ZACHARY ALANDREXEL UNIVERSITY, PA$418,625ZDA1
2025Probing the effect of opioids on HIV transcription and latency using a novel dual fluorescent and bioluminescent virus1R21DA063110-01CAMPBELL, LEEMOCCHETTI, ITALOGEORGETOWN UNIVERSITY, DC$234,000ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-DA-25-008: Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R21 Clinical Trial Not Allowed) | ScienceDex | ConductScience